Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Long-Term Investments (2016 - 2023)

Historic Long-Term Investments for Sangamo Therapeutics (SGMO) over the last 13 years, with Q2 2023 value amounting to $39.0 million.

  • Sangamo Therapeutics' Long-Term Investments fell 1861.53% to $39.0 million in Q2 2023 from the same period last year, while for Jun 2023 it was $39.0 million, marking a year-over-year decrease of 1861.53%. This contributed to the annual value of $29.8 million for FY2022, which is 6615.02% down from last year.
  • Per Sangamo Therapeutics' latest filing, its Long-Term Investments stood at $39.0 million for Q2 2023, which was down 1861.53% from $35.6 million recorded in Q1 2023.
  • Sangamo Therapeutics' 5-year Long-Term Investments high stood at $95.6 million for Q3 2021, and its period low was $5.0 million during Q1 2020.
  • Moreover, its 5-year median value for Long-Term Investments was $44.1 million (2020), whereas its average is $45.7 million.
  • Its Long-Term Investments has fluctuated over the past 5 years, first crashed by 7527.94% in 2019, then soared by 74862.0% in 2021.
  • Sangamo Therapeutics' Long-Term Investments (Quarter) stood at $21.8 million in 2019, then surged by 131.45% to $50.5 million in 2020, then soared by 74.49% to $88.2 million in 2021, then tumbled by 66.15% to $29.8 million in 2022, then surged by 30.8% to $39.0 million in 2023.
  • Its Long-Term Investments stands at $39.0 million for Q2 2023, versus $35.6 million for Q1 2023 and $29.8 million for Q4 2022.